Research ArticleOpen accessIn the author namesRibavirin Plus Therapy in Covid-19-A Single-Center ExperienceBudha Oinam Singh, Gaurav Chikara, Prasan Kumar Panda et al.COVID-19 infection has a similar clinical spectrum of disease presentation such as SARS and MERS in the past. These led to the assumption of the possibility to treat COVID-19 infection with antivirals which had been used to treat SARS and MERS. A retrospective analysis was done in symptomatic adult patients of COVID-19 infection to explore whether ribavirin antiviral combinations reduce … …American Journal of Pharmacology and Toxicology, Vol. 18, Issue 1 · 25 Jul 2023 · 8,610 accessesView PDFCite
Research ArticleOpen accessIn the author namesAssociation of Remdesivir with Poor Clinical Outcomes in COVID-19-A Single Center ExperienceRajat Ranka, Arjun, Prasan Kumar Panda et al.The need for an antiviral against COVID-19 prompted clinical trials worldwide and based on initial promising trends, remdesivir was widely used, including in India (compassionate use). Subsequent trials have been conflicting in their results and the utility of the drug has been widely debated. This is a record-based retrospective cohort study in a 1000-bedded government teaching hospital in North India. … …American Journal of Pharmacology and Toxicology, Vol. 17, Issue 1 · 3 Jun 2022 · 7,210 accessesView PDFCite